welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Antisense Therapeutics Announces Positive Results from Phase 2 Study of ATL1102 in DMD
Australian company Antisense Therapeutics announced encouraging results from its phase 2, open-label clinical trial of the company’s investigational therapy ATL1102 for treating Duchenne muscular dystrophy (DMD). The study met its primary endpoint, which was to assess the safety and tolerability of ATL1102 in patients with DMD who are non-ambulatory (unable to walk independently).
After six months of weekly, subcutaneous treatment with a low dose, the drug appeared to be safe and well tolerated in all participants with only minor side effects. Secondary endpoint results also seemed encouraging, as the drug lowered the average number of specific immune cells during the treatment period and largely improved measurements of functional capacity in seven of nine boys treated.
DMD is a genetic disease caused by a mutation in the dystrophin gene on the X chromosome that results in little or no production of dystrophin, an essential protein for keeping muscle cells intact.
rareRelated
-
A safety and efficacy study of ATL1102 in patients with Duchenne muscular dystrophyCurrent DMD therapies are aimed at incre...
-
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
-
Antisense Therapeutics to commence muscular dystrophy trialsAntisense Therapeutics is planning to un...
-
An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)The main purposes of this study are to s...
-
Santhera Completes Enrollment of Phase 3 SIDEROS Study With Puldysa® (Idebenone) in Duchenne Muscular Dystrophy (DM...Santhera Pharmaceuticals announces full ...
-
Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential...Catabasis Pharmaceuticals, Inc., a clini...
-
Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)The primary objective of this Expanded A...
-
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-infl...We report a first-in-patient study of va...
